Plenty of private longevity research companies are working on innovative studies aimed at diseases associated with the aging process, including cardiovascular disease, type 2 diabetes and various cancers. If they do go public one day, investors who have them on their radar already will be ahead of the game.
Here’s a short list of some of the top private longevity research companies making headlines today.
1. Sanumed
Sanumed is first on our list of longevity research companies. Based in San Diego, California, the company develops small-molecule, tissue-level therapeutic drugs aimed at treating numerous degenerative diseases, as well as many forms of cancer.
With the year almost over, here the Investing News Network profiles the five top NASDAQ medical device stocks of 2020.
Click here to read the previous top NASDAQ medical device stocks article.
The growing prevalence of chronic diseases such as cancer and diabetes is driving increasing innovation in medical device technology.
As of mid-December 2020, 49 new devices had been approved by the US Food and Drug Administration for the year, slightly up from the 46 approved in 2019.
Wearable medical devices and the integration of artificial intelligence into medical technology are two big trends in this life science sector. Moving forward, the global medical device industry is expected to grow from US$447.63 billion in 2019 to US$671.49 billion by 2027.
Alzheimer s Disease Treatment Stocks on the NASDAQ investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Leveljump Healthcare Corp. (TSXV:GOAL.P) (formerly Good2Go2 Corp.) (“Good2Go2” or the “Company”), is pleased to announce that on December 7, 2020, it closed its previously announced business combination involving Canadian Teleradiology Services, Inc. (“CTS”) as the “Qualifying Transaction” of the Company (as such term is defined within the meaning of Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange (the “Exchange”))
Leveljump Healthcare Corp. (TSXV:GOAL.P) (formerly Good2Go2 Corp.) (“Good2Go2” or the “Company”), is pleased to announce that on December 7, 2020, it closed its previously announced business combination involving Canadian Teleradiology Services, Inc. (“CTS”) as the “Qualifying Transaction” of the Company (as such term is defined within the meaning of Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange (the “Exchange”)). Subject to receiving final Exchange acceptance, the common shares of the Company a